Positron emission tomography (PET) in clinical oncology (Part III);Tomografía por emisión de positrones (PET) en oncología clínica (Parte III)

Revista Espanola de Medicina Nuclear

Volumn 21, Issue 4, 2002, Pages 304-323

  Cabrera Villegas, A ^a,d   Garcia Velloso Ma J ^b   Gamez Cenzano C ^c  

^a Servicio de Medicina Nuclear   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

^c Centro Andaluz de Diagnóstico PET   (Spain)

^d Centro PET (Servicio de Medicina Nuclear)   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE; DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ASTROCYTOMA; BRAIN LYMPHOMA; BRAIN TUMOR; BREAST CANCER; CANCER SCINTISCANNING; ESOPHAGUS CANCER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; NEUROENDOCRINE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PANCREAS CANCER; POSITRON EMISSION TOMOGRAPHY; REVIEW; THYROID CANCER; TOXOPLASMOSIS; ADULT; BREAST TUMOR; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIGESTIVE SYSTEM TUMOR; FEMALE; HEAD AND NECK TUMOR; LYMPH NODE METASTASIS; NEOPLASM; OVARY TUMOR; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; THYROID TUMOR;

ADULT; BRAIN NEOPLASMS; BREAST NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; NEOPLASMS; OVARIAN NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0036651555     PISSN: 02126982     EISSN: 1578200X     Source Type: Journal    
DOI: 10.1016/s0212-6982(02)72096-x     Document Type: Review

References (111)

1. Delbeke D. Oncological applications of FDG PET imaging. J Nucl Med 1999;40:1706-15.
2. Avril N, Schelling M, Dose J, Weber WA, Schwaiger M. Utility of PET in Breast Cancer. Clin Pos Imag 1999;2:261-71.
3. Flanagan FL, Dehdashti F, Siegel Ba. PET in Breast Cancer. Semm Nucl Med 1998;4:290-302.
4. Nemoto T, Vana J, Bedwani RN, Baker HW, McGregor FH, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer 1980;45:2917-24.
5. 18fluorine)- fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996;4,88: 1204-9.
6. Mariani G, Moresco L, Viale G, Villa G, Bagnasco M, Canavese G, et al. Radioguided sentinel lymph node biopsy in breast cancer surgery. J Nucl Med 2001;42:1198-215.
7. Morrow M, Foster R. Staging of breast cancer: a new rationale for interna mammary node biopsy. Arch Surg 1981;116:748.
8. 18FDG PET: differing metabolic activity in osteoblastic and osteolytic lesions. J Clin Oncol 1998;16:3375-9.
9. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993;11:2101-11.
10. 18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000;18:1689-95.
11. 18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000;18:1676-88.
12. 18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma. J Nucl Med 1991;32:1526-31.
13. 18F]fluoro-17 beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy. Clin Cancer Res 1996;2:933-9.
14. Vokes EE, Weichselbaum RR, Lippman SM, Hong WK. Head and neck cancer. New Engl J Med 1993;328:184-94.
15. 18fluorine fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-74.
16. Som PM. Detection of metastasis in cervical lymph nodes: CT and RM criteria and differential diagnosis. Am J Radiol 1992;158:961-9.
17. Friedman M, Mafee MF, Pacella BL Jr, Strorigl TL, Dew LL, Toriumi DM. Rationale for elective neck dissection in 1990. Laryngoscope 1990;100:54-9.
18. Valdés-Olmos RA, Balm AJM, Koops W, Loftus BM, Hoefnagel CA, Hilgers FJ. La medicina nuclear en el diagnóstico por la imagen del cáncer de cabeza y cuello. Rev Esp Med Nucl 1997;16:128-37.
19. 18fluorine-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous-cell carcinomas. J Nucl Med 1995;36:1747-57.
20. Poch Broto J, Carreras Delgado JL. La tomografía por emisión de positrones en carcinomas de cabeza y cuello. Acta Otorrinolaring Esp 1997;48:423-8.
21. Bailet JW, Abemayor E, Jabour BA, Hawkins RA, Ho C, Ward PH. Positron emission tomography: a new, precise imaging modality for detection of primary head and neck tumors and assessment of cervical adenopathy. Laryngoscope 1992;102:281-8.
22. Braams JW, Pruim J, Freling NJ, Nikkels PG, Roodenburg JL, Boering G, et al. Detection of lymph node metastases of squamous-cell cancer of the head and neck with FDG-PET and MRI. J Nucl Med 1995;36:211-6.
23. Rege S, Maass A, Chaiken L, Hoh CK, Choi Y, Lufkin R, et al. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 1994;73:3047-58.
24. 18F)FDG in head and neck tumors after irradiation. Eur J Nucl Med 1998;25:1028.
25. Rege SD, Chaiken L, Hoh CK, Choi Y, Lufkin R, Anzai Y, et al. Change induced by radiation therapy in FDG uptake in normal and malignant structures of the head and neck: quantitation with PET. Radiology 1993;189:807-12.
26. Chaiken L, Rege S, Hoh C, Choi Y, Jabour B, Juillard G, et al. Positron emission tomography with fluorodeoxyglucose to evaluate tumor response and control after radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:455-64.
27. Haberkorn, Strauss LG, Reisser C, Haag D, Dimitrakopoulou A, Ziegler S, et al. Glucose uptake, perfusion, and cell proliferation in head and neck tumors: relation of positron emission tomography to flow cytometry. J Nucl Med 1991;32:1548-55.
28. Greven KM, Williams DW, Keyes JW, McGuirt WF, Harkness BA, Watson NE, et al. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer. Int J Radiat Oncol Biol Phys 1994;29:841-5.
29. Bailet JW, Sercarz JA, Abemayor E, Anzai Y, Lufkin RB, Hoh CK. The use of positron emission tomography for early detection of recurrent head and neck squamous cell carcinoma in postradiotherapy patients. Laryngoscope 1995;105:135-9.
30. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose imaging: a method to assess the proliferative activity of human cancer in vivo. Comparison with DNA flow cytometry in head and neck tumors. Cancer 1988;61:1776-81.
31. 18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200:135-41.
32. Reisser C, Haberkorn U, Dimitrakopoulou Strauss A, Seifert E, Strauss LG. Chemotherapeutic management of head and neck malignancies with positron emission tomography. Arch Otolaryngol Head Neck Surg 1995;121:272-6.
33. 18F-fluorodeoxyglucose positron emission tomography. Head Neck 1997;19:666-74.
34. Haberkorn U, Strauss LG, Dimitrakopoulou A, Seiffert E, Oberdorfer F, Ziegler S, et al. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy. J Nucl Med 1993;34:12-7.
35. McGuirt WF, Greven KM, Keyes JW, Williams DW, Watson EN, Geisinger KR, et al. Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol. 1995;104:274-8.
36. McGuirt WF, Keyes JW, Greven KM, Williams DW, Watson EN, Cappellari JO. Preoperative identification of benign versus malignant parotid masses: a comparative study including positron emission tomography. Laryngoscope 1995;105:579-84.
37. Wong WL, Chevretton E, McGurk M, Croft D. PET-FDG imaging in the clinical evaluation of head and neck cancer. J R Soc Med 1995;88:469-73.
38. Kubota R, Kubota K, Yamada S, Tada M, Takahashi T, Iwata R, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med 1995;36:484-92.
39. 18fluorine-fluorodeoxyglucose and 11carbon-methionine in head and neck cancer. J Nucl Med 1993;34:1711-6.
40. 18Fluorine fluorodeoxyglucose positron emission tomograpgy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1996;23:312-9.
41. 18fluorine-fluorodeoxyglucose. J Nucl Med 1987;28:910-4.
42. 131I. Nuklearmedizin 1995;34:127-34.
43. 18fluoro-2-Deoxy-d-Glucose by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993:1090-3.
44. 131Iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
45. 99mTc-Sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
46. 18Fluorine fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
47. 131iodine whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 1997;24:1342-8.
48. 18fluorine fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 2000;27:490-6.
49. 18fluorinedeoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Invest 1997;20:527-30.
50. Rufini V, Salvatori M, Garganese MC, Di Giuda D, Lodovica Maussier M, Troncone L. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma. Rays 2000;25:273-82.
51. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1,000 patients. Eur J Nucl Med 1993;20:716-31.
52. 18F] fluorodeoxyglucose and positron emission tomography. Neurology 1982;32:1323-9.
53. Hoffman JM, Waskin HA, Schifter T, Hanson MW, Gray L, Rosenfeld SS, et al. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS. J Nucl Med 1993;34:567-75.
54. Villringer K, Jager H, Dichgans M, Ziegler S, Poppinger J, Herz M, et al. Differential diagnosis of CNS lesions in AIDS patients by FDG-PET. J Comput Assist Tomogr 1995;19:532-6.
55. 18F-fluorodeoxyglucose uptake in the differentiation of low-grade from highgrade brain tumors with PET. Radiology 1995;195:47-52.
56. Ricci PE, Karis JP, Heiserman JE, Fram EK, Bice AN, Drayer BP. Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of positron emission tomography? AJNR Am J Neuroradiol 1998;19:407-13.
57. Di Chiro G, Fulham MJ. Virchow's shackles: can PET-FDG challenge tumor histology? AJNR Am J Neuroradiol 1993;14:524-7.
58. 18Fluorodeoxyglucose uptake and survival of patients with suspected recurrent malignant glioma. Cancer 1997;79:115-26.
59. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996;17:197-8.
60. Torizuka T, Tamaki N, Inokuma T, Magata Y, Sasayama S, Yonekura Y, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-7.
61. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, precancerous, and neopastic tissues. Cancer Res. 1955;15:105-8.
62. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133:510-5.
63. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr 1992;16:684-9.
64. 18F-labelled deoxyglucose: method and first results. Nucl Med Commun 1993;14:596-601.
65. Kato T, Fukatsu H, Ito K, Tadokoro M, Ota T, Ikeda M, et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 1995;22:32-9.
66. 18fluorine)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 1995;195:339-44.
67. Delbeke D, Rose DM, Chapman WC, Pinson CW, Wright JK, Beauchamp RD, et al. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 1999;40:1784-91.
68. 18F]fluoro-2- deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer. Br J Surg 1999;86:194-9.
69. Flamen P, Lerut A, Van Cutsem E, De Wever W, Peeters M, Stroobants S, et al. Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma. J Clin Oncol 2000;18:3202-10.
70. Luketich JD, Friedman DM, Weigel TL, Meehan MA, Keenan RJ, Townsend DW, et al. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans. Ann Thorac Surg 1999;68:1133-6.
71. Choi JY, Lee KH, Shim YM, Lee KS, Kim JJ, Kim SE, et al. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET. J Nucl Med 2000;41:808-15.
72. 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997;168:417-24.
73. Block MI, Patterson GA, Sundaresan RS, Bailey MS, Flanagan FL, Dehdashti F, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg 1997;64:770-6.
74. Flamen P, Lerut A, Van Cutsem E, Cambier JP, Maes A, De Wever W, et al. The utility of positron emission tomography for the diagnosis and staging of recurrent esophageal cancer. J Thorac Cardiovasc Surg 2000;120:1085-92.
75. Einhorn W, Nilsson B, Stovall K. Factors influencing survival in carcinoma of the ovary. Cancer 1985;55:2015-9.
76. Hoskins WJ, Pérez CA, Young RC, eds. Epithelial ovarian cancer. En: Principles and practice of gynecologic oncology. Philadelphia JB. Lippincott Company, 1992.
77. Mendiola C, Gómez Martín C, Cortés-Funes H. Cáncer de ovario. En: González Baron M. Oncología clínica 2. Patología especial. McGraw-Hill. Interamericana. Madrid, 1998;299-311.
78. Wahl RL, Hutchins GD, Roberts J. FDG-PET imaging of ovarian cancer: initial evaluation in patients. J Nucl Med 1991;32:982.
79. 18F-FDG). Ginecology Oncology 1993;51:197-204.
80. th Annual International PET conference, Institute for Clinical PET, Fairfax, Virginia, 1995.
81. Avril N, Janicke F, Dose J, et al. FDG-PET evaluation of pelvic masses suspicious for primary or recurrent ovarian cancer. J Nucl Med 1994;35:231P.
82. 18F-fluorodeoxyglucose. Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1997;166:62-8.
83. 18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results]. Nuklearmedizin 1997;36:228-33.
84. 18F-Fluorodeoxyglucose. Nuklearmedizin 1999;38:101-7.
85. 11Carbon-Methionine: a PET study. J Nucl Med 1995;36:2196-200.
86. 18F-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma. Gynecol Oncol 1993;51:175-81.
87. 18F-fluoro-2-deoxy-D- glucose. J Comput Assist Tomogr 1993;17:582-9.
88. Casey MJ, Gupta NC, Muths Ck. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol 1994;53:331-8.
89. 18F-FDG PET in comparison to CT in ovarian cancer. Eur J Nucl Med 1997;24:1049.
90. Geary M, Foley M, Lenehan P. Recurrent ovarian carcinoma diagnosis and second-line therapy. Ir-Med-J. 1995;88:698-70.
91. Baum RP, Niesen A, Schröder O, et al. A prospective evaluation of whole-body FDG-PET, CT scan and immunoscintigraphy in the detection of ovarian carcinoma recurrences. Eur J Nucl Med 1998;25:942.
92. 18fluorine-2-deosyglucose for detecting recurrent ovarian carcinoma. Initial report. J Reprod Med 1999;44:775-8.
93. 125CA. Rev Esp Med Nucl 2001;3:178.
94. Hebart H, Erley C, Kaskas B, Mayer R, Konig M, Einsele H, et al. PET helps to diagnose tumor emboli and residual disease in choriocarcinoma. Ann Oncol 1996;7:416-8.
95. 18fluorine)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. Gynecol Oncol 1993;49:383-8.
96. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol 2001;19:3745-9.
97. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: potential impact on treatment. Int J Gynecol Cancer 2001;11:263-71.
98. Hoh CK, Seltzer MA, Franklin J, de Kernion JB, Phelps ME, Belldegrun A. Positron emission tomography in urological oncology. J Urol 1998;159:347-56.
99. 18fluorine-labelled deoxyglucose: utility in localized and advanced prostate cancer. BJU Int 1999;84:1028-31.
100. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol 1996;14:1637-41.
101. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumour at relapse. Br J Cancer 2000;83:863-9.
102. Cremerius U, Effert PJ, Adam G, Sabri O, Zimmy M, Wagenknecht G, et al. FDG PET for detection and therapy control of metastatic germ cell tumor. J Nucl Med 1998;39:815-22.
103. Adler LP, Blair HF, Makley JT, Williams RP, Joyce MJ, Leisure G, et al. Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 1991;32:1508-12.
104. Smith MA, O'Doherty MJ. Positron emission tomography and the orthopaedic surgeon. J Bone Joint Surg Br 2000;82:324-5.
105. 18Fluorine-fluorodeoxyglucose assessment of glucose metabolism in bone tumors. J Nucl Med 1998;39: 810-5.
106. Wu H, Dimitrakopoulou-Strauss A, Heichel TO, Lehner B, Bernd L, Ewerbeck V. Quantitative evaluation of skeletal tumours with dynamic FDG PET: SUV in comparison to Patlak analysis. Eur J Nucl Med 2001;28:704-10.
107. 18fluorine]- fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology 1996;199:743-50.
108. 18fluorine]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG. J Nucl Med 1995;36:644-50.
109. 18fluorine-FDG PET in metastatic carcinoid. J Nucl Med 1997;38:1382-3.
110. Orlefors H, Sundin A, Ahlstrom H, Bjurling P, Bergstrom M, Lilja A, et al. Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors J Clin Oncol 1998;16:2534-41.
111. 18fluorine fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 1998;25:79-83.